{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:21:59Z","timestamp":1790270519595,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Major Science and Technology Support Project of Shanghai Science and Technology Commission","award":["13401902800"],"award-info":[{"award-number":["13401902800"]}]},{"name":"National Natural Science Foundation of China: Study on Reducing airway hyperresponsiveness of Gastroesophageal reflux cough by regulating RhoA\/ROCK signaling Pathway with ADAM33 by Tongjianghewei Fang","award":["82205022"],"award-info":[{"award-number":["82205022"]}]},{"name":"\"Key Talents Training Program for Clinical Research\", Affiliated Hospital of Shanghai University of Traditional Chinese Medicine","award":["2023LCRC27"],"award-info":[{"award-number":["2023LCRC27"]}]},{"name":"Reserve Outstanding TCM Talents of Shanghai University of Traditional Chinese Medicine","award":["[2020] 10"],"award-info":[{"award-number":["[2020] 10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-024-02030-z","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:02:47Z","timestamp":1726729367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Shugan Hewei formula combined with rabeprazole in refractory gastroesophageal reflux disease: randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"29","author":[{"given":"Xiulian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"3","key":"2030_CR1","first-page":"214","volume":"115","author":"DM Clarrett","year":"2018","unstructured":"Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). Mo Med. 2018;115(3):214\u20138.","journal-title":"Mo Med"},{"issue":"2","key":"2030_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","volume":"154","author":"JE Richter","year":"2018","unstructured":"Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):267\u201376.","journal-title":"Gastroenterology"},{"issue":"1","key":"2030_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/SGA.0000000000000359","volume":"42","author":"J Chen","year":"2019","unstructured":"Chen J, Brady P. Gastroesophageal reflux disease: pathophysiology, diagnosis, and treatment. Gastroenterol Nurs. 2019;42(1):20\u20138.","journal-title":"Gastroenterol Nurs"},{"issue":"5","key":"2030_CR4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/j.gastro.2019.12.014","volume":"158","author":"SD Delshad","year":"2020","unstructured":"Delshad SD, et al. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158(5):1250-1261.e2.","journal-title":"Gastroenterology"},{"issue":"2","key":"2030_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/joim.13148","volume":"289","author":"NJ Talley","year":"2021","unstructured":"Talley NJ, Zand Irani M. Optimal management of severe symptomatic gastroesophageal reflux disease. J Intern Med. 2021;289(2):162\u201378.","journal-title":"J Intern Med"},{"issue":"1","key":"2030_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10620-020-06141-5","volume":"66","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci. 2021;66(1):19\u201328.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2030_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000342234","volume":"86","author":"S Kunsch","year":"2012","unstructured":"Kunsch S, et al. Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion. 2012;86(4):315\u201322.","journal-title":"Digestion"},{"issue":"1","key":"2030_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2050640612473964","volume":"1","author":"F Zerbib","year":"2013","unstructured":"Zerbib F, et al. Modern medical and surgical management of difficult-to-treat GORD. United Eur Gastroenterol J. 2013;1(1):21\u201331.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"2030_CR9","first-page":"CD002095","volume":"2013","author":"KE Sigterman","year":"2013","unstructured":"Sigterman KE, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;2013(5):CD002095.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2030_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/j.gastro.2010.05.016","volume":"139","author":"ES Dellon","year":"2010","unstructured":"Dellon ES, Shaheen NJ. Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease. Gastroenterology. 2010;139(1):7-13.e3.","journal-title":"Gastroenterology"},{"key":"2030_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fphar.2020.00884","volume":"11","author":"YK Dai","year":"2020","unstructured":"Dai YK, et al. Different traditional herbal medicines for the treatment of gastroesophageal reflux disease in adults. Front Pharmacol. 2020;11:884.","journal-title":"Front Pharmacol"},{"issue":"28","key":"2030_CR12","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3748\/wjg.v27.i28.4710","volume":"27","author":"Z Li","year":"2021","unstructured":"Li Z, et al. Modified Xiaochaihu Decoction for gastroesophageal reflux disease: a randomized double-simulation controlled trial. World J Gastroenterol. 2021;27(28):4710\u201321.","journal-title":"World J Gastroenterol"},{"key":"2030_CR13","first-page":"1500660","volume":"2022","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Treatment of the gastroesophageal reflux disease with chinese herbal medicine (BanxiaXiexin Decoction): evidence from meta-analysis. Evid Based Complement Alternat Med. 2022;2022:1500660.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2030_CR14","first-page":"9647003","volume":"2022","author":"F Li","year":"2022","unstructured":"Li F, et al. Herbal Medicine Hewei Jiangni decoction is noninferior to oral omeprazole for the treatment of nonerosive gastroesophageal reflux disease: a randomized double-blind, and double-dummy controlled trail. Evid Based Complement Alternat Med. 2022;2022:9647003.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"10","key":"2030_CR15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00535-013-0896-9","volume":"49","author":"K Tominaga","year":"2014","unstructured":"Tominaga K, et al. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol. 2014;49(10):1392\u2013405.","journal-title":"J Gastroenterol"},{"key":"2030_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fphar.2020.00076","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, et al. Efficacy of Chinese herbal formula Sini Zuojin decoction in treating gastroesophageal reflux disease: clinical evidence and potential mechanisms. Front Pharmacol. 2020;11:76.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2030_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/00365521.2022.2163185","volume":"58","author":"Z Ge","year":"2023","unstructured":"Ge Z, et al. Using deep learning and explainable artificial intelligence to assess the severity of gastroesophageal reflux disease according to the Los Angeles classification system. Scand J Gastroenterol. 2023;58(6):596\u2013604.","journal-title":"Scand J Gastroenterol"},{"issue":"16","key":"2030_CR18","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3390\/polym15163485","volume":"15","author":"Y Herdiana","year":"2023","unstructured":"Herdiana Y. Chitosan nanoparticles for gastroesophageal reflux disease treatment. Polymers (Basel). 2023;15(16):3485.","journal-title":"Polymers (Basel)"},{"issue":"5","key":"2030_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/SLE.0b013e3182628913","volume":"22","author":"C Zhang","year":"2012","unstructured":"Zhang C, et al. A preliminary investigation of laparoscopic fundoplication treatment on gastroesophageal reflux disease-related respiratory symptoms. Surg Laparosc Endosc Percutan Tech. 2012;22(5):406\u20139.","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"4","key":"2030_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14075","volume":"33","author":"F Zerbib","year":"2021","unstructured":"Zerbib F, et al. ESNM\/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4): e14075.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"2030_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.psym.2015.10.007","volume":"57","author":"CE Ho","year":"2016","unstructured":"Ho CE, et al. GERD: an alternative perspective. Psychosomatics. 2016;57(2):142\u201351.","journal-title":"Psychosomatics"},{"issue":"5","key":"2030_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrgastro.2016.50","volume":"13","author":"E Scarpellini","year":"2016","unstructured":"Scarpellini E, et al. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13(5):281\u201394.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"2030_CR23","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/nmo.12638","volume":"27","author":"S Tolone","year":"2015","unstructured":"Tolone S, et al. Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? Neurogastroenterol Motil. 2015;27(10):1423\u201331.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"2030_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/nmo.12477","volume":"27","author":"PJ Kahrilas","year":"2015","unstructured":"Kahrilas PJ, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160\u201374.","journal-title":"Neurogastroenterol Motil"},{"key":"2030_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12970","author":"CA Reddy","year":"2017","unstructured":"Reddy CA, Patel A, Gyawali CP. Impact of symptom burden and health-related quality of life (HRQOL) on esophageal motor diagnoses. Neurogastroenterol Motil. 2017. https:\/\/doi.org\/10.1111\/nmo.12970.","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"2030_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2036.2004.02298.x","volume":"21","author":"P Zentilin","year":"2005","unstructured":"Zentilin P, et al. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Aliment Pharmacol Ther. 2005;21(1):29\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2030_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11894-005-0033-x","volume":"7","author":"S Emerenziani","year":"2005","unstructured":"Emerenziani S, Sifrim D. Gastroesophageal reflux and gastric emptying, revisited. Curr Gastroenterol Rep. 2005;7(3):190\u20135.","journal-title":"Curr Gastroenterol Rep"},{"key":"2030_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)63480-0","author":"V Boecxstaens","year":"2013","unstructured":"Boecxstaens V, et al. Tu2125 refractory GERD patients display increased visceral hypersensitivity for thermal chemical and mechanical esophageal stimulation. Gastroenterology. 2013. https:\/\/doi.org\/10.1016\/S0016-5085(13)63480-0.","journal-title":"Gastroenterology"},{"issue":"10","key":"2030_CR29","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.cgh.2013.10.026","volume":"12","author":"WO Rohof","year":"2014","unstructured":"Rohof WO, et al. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2014;12(10):1647\u201355.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2030_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1053\/j.gastro.2014.10.010","volume":"148","author":"F Ates","year":"2015","unstructured":"Ates F, et al. Mucosal impedance discriminates GERD from non-GERD conditions. Gastroenterology. 2015;148(2):334\u201343.","journal-title":"Gastroenterology"},{"issue":"2","key":"2030_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1756283X16681701","volume":"10","author":"R Fass","year":"2017","unstructured":"Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017;10(2):243\u201351.","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"2030_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1365-2036.2004.01949.x","volume":"19","author":"J Hammer","year":"2004","unstructured":"Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther. 2004;19(10):1105\u201310.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10 Suppl 2","key":"2030_CR33","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/ajhp\/62.10_Supplement_2.S24","volume":"62","author":"JW Devlin","year":"2005","unstructured":"Devlin JW. Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations. Am J Health Syst Pharm. 2005;62(10 Suppl 2):S24-30.","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"2030_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11894-018-0641-x","volume":"20","author":"ME Riehl","year":"2018","unstructured":"Riehl ME, Chen JW. The proton pump inhibitor nonresponder: a behavioral approach to improvement and wellness. Curr Gastroenterol Rep. 2018;20(7):34.","journal-title":"Curr Gastroenterol Rep"},{"issue":"27","key":"2030_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001111","volume":"94","author":"W Ling","year":"2015","unstructured":"Ling W, et al. Common mechanism of pathogenesis in gastrointestinal diseases implied by consistent efficacy of single chinese medicine formula: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2015;94(27): e1111.","journal-title":"Medicine (Baltimore)"},{"key":"2030_CR36","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2147\/DDDT.S348985","volume":"16","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, et al. Network pharmacology analysis of Hewei Jiangni granule for gastroesophageal reflux disease and experimental verification of its anti-neurogenic inflammation mechanism. Drug Des Devel Ther. 2022;16:1349\u201363.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2030_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13063-021-05471-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. Efficacy and safety of the Chinese herbal formula Hewei Jiangni recipe for NERD with cold-heat complex syndrome: study protocol for a double-blinded randomized controlled trial. Trials. 2021;22(1):545.","journal-title":"Trials"},{"issue":"5","key":"2030_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1142\/S0192415X15500524","volume":"43","author":"W Ling","year":"2015","unstructured":"Ling W, et al. Consistent efficacy of Wendan decoction for the treatment of digestive reflux disorders. Am J Chin Med. 2015;43(5):893\u2013913.","journal-title":"Am J Chin Med"},{"key":"2030_CR39","unstructured":"Li X et al. Acupuncture for gastrointestinal diseases. Anat Rec (Hoboken), 2022."},{"issue":"41","key":"2030_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022454","volume":"99","author":"W Lin","year":"2020","unstructured":"Lin W, et al. Efficacy and safety of traditional Chinese herbal formula combined with western medicine for gastroesophageal reflux disease: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(41): e22454.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2030_CR41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0009-9236(99)70075-5","volume":"65","author":"T Furuta","year":"1999","unstructured":"Furuta T, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65(5):552\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"2030_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","volume":"13","author":"T Ishizaki","year":"1999","unstructured":"Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors\u2013emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2030_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00535-011-0488-5","volume":"47","author":"K Tominaga","year":"2012","unstructured":"Tominaga K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47(3):284\u201392.","journal-title":"J Gastroenterol"},{"issue":"11","key":"2030_CR44","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s00535-019-01588-4","volume":"54","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, et al. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors: usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. J Gastroenterol. 2019;54(11):972\u201383.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2030_CR45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12906-023-04283-3","volume":"23","author":"NY Ha","year":"2023","unstructured":"Ha NY, Kim JW, Kim J. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial. BMC Complement Med Ther. 2023;23(1):444.","journal-title":"BMC Complement Med Ther"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-02030-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:07:35Z","timestamp":1726729655000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-02030-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2030"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-02030-z","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from the Ethics Committee of Yueyang Hospital of Integrative Medicine affiliated with Shanghai University of Traditional Chinese Medicine (Ethics No. 2013-060). The written informed consent was obtained from all participating patients. This clinical trial was conducted in strict accordance with the Declaration of Helsinki (Edinburgh 2000 version) and relevant Chinese clinical trial research norms and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"466"}}